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Abstract
Giant cell arteritis (GCA) is the most common vasculitis in adults, with the inci-
dence increasing with the advancing age. The aorta and its branches, especially the 
carotid extracranial branches, are the classic targets of inflammation in GCA. Visual 
loss, upper limb ischemia, and stroke are complications described. Suspicion of 
GCA is a medical emergency, and patients need to be quickly diagnosed/treated to 
prevent irreversible damage. Headache is the most common symptom, and a new-
onset headache in older adults should always raise the suspicion of GCA. Patients 
may also present with scalp tenderness or tongue/jaw pain. GCA is often found to 
be the cause of an obscure-origin fever in older patients. A positive temporal artery 
biopsy is considered the gold standard for the diagnosis, but imaging techniques 
enable the assessment of cranial and extracranial arteries and the aorta. Ultrasound 
of temporal arteries is recommended and noncompressible “halo” sign is the typical 
finding. PET, MRI, or CT may be useful for the detection of the disease in the aorta 
and other vessels. The treatment must be started promptly with prednisone 1 mg/
kg/day. When visual symptoms/unilateral visual loss is present, methylpredniso-
lone pulse is recommended. Methotrexate, leflunomide and tocilizumab may be 
effective and well-tolerated glucocorticoid-sparing agents in GCA. Cardiovascular 
diseases are the leading causes of death in patients.
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1. Introduction
The first description of giant cell arteritis dates from 1890 by Hutchinson, who 
described an 80-year-old man with painful and inflamed temporal arteries which 
prevented him from wearing his hat [1]. Forty-seven years later Horton, Magath, 
and Brown described similar cases and called the syndrome temporal arteritis [2]. 
Originally thought to be a localized, self-limiting, and benign disorder, inflamma-
tion of the temporal arteries is now recognized as part of a widespread arteritis 
which untreated can lead to blindness and death.
Giant cell arteritis (GCA), previously called temporal arteritis and also known 
as Horton’s disease, is defined by the 2012 Chapel Hill Consensus Conference 
as “arteritis, often granulomatous, usually affecting the aorta and/or its major 
branches, with a predilection for the branches of the carotid and vertebral arteries; 
often involves the temporal artery; onset usually in patients older than 50; often 
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associated with polymyalgia rheumatica” [3]. It is the most common primary sys-
temic vasculitis in adults, mostly seen in North America and Western Europe, with 
the incidence increasing with the advancing age. Women are more affected than 
men in a 2.5:1 ratio. GCA classically targets large vessels with predominance for the 
aorta and its branches. Arterial inflammation may lead to vascular damage which 
can result in stenosis, occlusions, and even aneurysms. Therefore, this condition is 
related to serious loss of function including visual loss, upper limb ischemia, and 
stroke. Suspicion of giant cell arteritis is a medical emergency, and patients need 
to be quickly diagnosed and treated to prevent irreversible consequences of vessel 
inflammation.
2. Pathogenesis
The immune and pathogenetic pathways responsible for the inflammation on the 
arterial walls in GCA are not fully understood yet. As in other autoimmune diseases, 
it is believed to be an environmental-triggered response occurring in genetic-predis-
posed individuals. The fact that it only affects older patients suggests that age-related 
damage on the vessel walls also plays a role in the development of the arteritis [4].
There is evidence of a cyclic pattern and yearly incidence of the onset of GCA, 
which led to the search for an environmental agent responsible for the initializa-
tion of the immune response. Many bacterial agents and viruses have been under 
research (Chlamydia pneumonia, Burkholderia, cytomegalovirus, erythrovirus B19, 
herpes simplex, and parainfluenzae 1, among others), but the studies failed in finding 
a causal correlation between infections and GCA so far [4].
GCA is associated with the major histocompatibility class II (MHC-II), par-
ticularly with HLA-DRB1*04 alleles [5]. Outside the MHC region, variants on the 
PTPN22 locus and other genes related to vascular response to inflammation and 
vascular remodeling, such as plasminogen and prolyl 4-hydroxylase subunit alpha 
2, also increased the risk of GCA.
Age-related damage on the arterial wall also has a role on the pathogenesis. 
There are biochemical and structural modifications in the vessel leading to loss of 
self-tolerance. Differences in the DNA methylation level of several genes have been 
reported in temporal arteries from GCA patients comparing with non-GCA controls.
There is evidence that the inflammation starts in the adventitia and progresses 
to the other layers of the arterial wall, culminating in transmural damage. Activated 
dendritic cells (DCs) have a central role in the immune response of GCA. These 
cells are present in the adventitia and express Toll-like receptors, which are acti-
vated via pathogen-associated molecular patterns (PAMPs) or microorganism-
associated molecular patterns (MAMPs). The activation of DC breaks immune 
tolerance and renders the arteries, considered otherwise an immune privileged site, 
susceptible to inflammatory injury. DCs activate CD4+ T lymphocytes through co-
stimulatory molecules (CD80 and CD86) and class II MHC. DC depletion in mice 
models with GCA strongly decreased vasculitis lesions, emphasizing its importance 
on the immune response.
Activated DCs produce cytokines such as IL-6, IL-18, IL-23, IL-32, and IL-33, 
which are chemotactic for T lymphocytes. T cells that infiltrate the temporal arteries 
from GCA patients are enriched Th1, Th17, and Th9 cells. Th1-response polariza-
tion via IL-12 synthesizes IFN-γ, and Th17 cells produce IL-17. While Th17 cells are 
inhibited by glucocorticoids, the Th1 response is not, being this last one implicated 
in sustaining chronic disease activity in GCA [6].
IFN-γ seems to be important for the development of vasculitis. The cytokine 
panel described above is found in both GCA patients and PMR patients without 
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GCA, but INF-γ is only present in individuals with GCA. IFN-γ expression, in 
fact, is associated with increased risk of ischemic complications. Vascular smooth 
muscle cells, induced by IFN-γ, produce chemokines (CCL2, CXCL9, CXCL10, and 
CXCL11), leading to the recruitment of monocytes that merge to form multinucle-
ated giant cells, the hallmark of GCA. The chemokines recruit more immune cells, 
amplifying the inflammatory response. Monocytes differentiate into macrophages 
in the arterial wall and produce IL-6, IL-1β, and TNF-α, responsible for the systemic 
inflammatory response which is characteristic of GCA. Toxic substances for the 
arteries are also produced by macrophages, such as reactive oxygen species, matrix 
metalloproteinase-2 (MMP-2), and MMP-9, which destroy cellular matrix proteins 
and cause destruction of the media and digestion of the internal elastic lamina.
Th17 cells appear to be important in the initial stages of the disease, producing 
IL-17, IL-21, IL-22, and CCL20. IL-17 leads to the recruitment of macrophages, 
while IL-21 enhances the differentiation of cytotoxic cells, and IL-22 mediates 
hepatocyte stimulation and acute-phase amplification. CCL20 facilitates the 
recruitment of more DCs and T cells.
The vascular smooth muscle cells in inflamed arteries are believed to acquire 
pro-inflammatory properties and produce several growth factors (vascular endo-
thelial growth factor (VEGF) and platelet-derived growth factor (PDGF), among 
others), causing intimal hyperplasia and vascular occlusion.
B cells are not present in the arterial wall of all the patients with GCA, suggesting 
that its effect is not crucial in the pathogenesis. However, when present, they are acti-
vated and contribute for the amplification of the immune response and inflammation.
Finally, defects in immune checkpoints have also been studied and appear to 
play a role in the immune activation observed in GCA. T cells express programmed 
death-1 (PD-1), which binds to its receptor in antigen-presenting cells, inducing 
T cell anergy and apoptosis, and the production of IL-10 by T cells or their polar-
ization into T-reg lymphocytes. A defect in the immunoprotective PD-1/PD-L1 
immune checkpoint has been reported in GCA patients.
3. Clinical features
Headache is the most common symptom of GCA, and a new-onset headache 
(or worsening of a preexisting headache) in older adults should always raise the 
suspicion of this condition. The installation of the pain is usually acute/subacute. 
The typical pattern is a temporal headache, continuous throughout the day and 
resistant to standard analgesia, but it can also be felt over other cranial areas or be 
diffuse. Patients may also present with scalp tenderness or tongue/jaw pain. Jaw 
claudication, seen in 45% of the patients, is a relatively specific sign and correlates 
with temporal artery biopsy positivity.
Total or partial visual loss affects 15–20% of patients, mostly at disease onset. 
The main cause is anterior ischemic optic neuropathy due to vasculitis of the pos-
terior ciliary arteries, which are branches of the ophthalmic artery and responsi-
ble for the blood supply of the optic nerve and the choroid. The optic neuropathy 
leads to visual loss, which is usually painless and with rapid onset. Occasionally, 
posterior ischemic optic neuropathy, occlusive vasculopathy of the central artery 
of the retina, or cortical ischemia can cause visual loss too. Blindness is irrevers-
ible in most cases, and when one eye is affected, the other one will likely (in half 
of the cases) be diseased too in a few days if the treatment is not promptly started. 
About 10% of patients develop amaurosis fugax, visual hallucinations, or diplo-
pia, which are considered premonitory signs and can progress to blindness in half 
of the cases.
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Systemic manifestations, such as fever, weight loss, and fatigue, are frequent 
(42, 50, and 40%, respectively). Some patients present only with constitutional 
symptoms, without headache or visual changes, and in those cases, the diagnosis 
can be challenging. GCA can be the cause of an obscure-origin fever in older 
patients.
Polymyalgia rheumatica (PMR) is the most common extracranial manifestation 
of GCA, and it may also be the first clinical sign of a vasculitis relapse. It is defined by 
pain/tenderness in proximal arms and legs, with morning stiffness and fast improve-
ment with low-dose glucocorticoid treatment. PMR is seen in 50% of the patients with 
GCA, while only 20% of the patients with PMR have clinical signs of GCA. However, 
in patients with PMR with persistently high inflammatory markers and insufficient 
response to glucocorticoids, a careful investigation may reveal an oligo-symptomatic 
GCA requiring more aggressive treatment. GCA and PMR are different conditions that 
share many common features: they occur almost exclusively in patients aged 50 years 
or older, have similar gender ratios, are associated with the HLA-DRB1*04 alleles 
and increased levels of serum acute-phase reactants, and respond to glucocorticoid 
therapy.
GCA is a systemic vasculitis with predominance for the aorta and its branches. 
Therefore, the patients may also present with chest pain and limb claudication. 
Large-vessel disease may complicate with aneurysms or stenosis development, 
resulting in increased mortality due to cardiovascular disease. Many patients with 
GCA develop clinical manifestations of large-vessel involvement, such as arm 
claudication (4%) and arterial bruits (21%).
Cerebrovascular events are less common ischemic complications, seen in 15% 
of the patients. They are mostly due to occlusive vasculitis of the carotid or verte-
brobasilar arteries. Transitory or persistent ischemic attacks are the most common 
neurologic manifestations, but cognitive impairment and neuropathy are other 
possible complications. Neuropsychiatric symptoms (dementia, mood disorders, 
and psychosis) affect 3% of the patients. Audio vestibular dysfunction leading to 
sensorineural hearing loss has also been described in GCA.
Infrequent clinical manifestations include tongue, scalp or lip necrosis, and 
facial/submandibular swelling. Unlike visual loss, ischemic necrosis tends to 
improve after the glucocorticoid treatment is started. Peripheral synovitis is found 
in 15% of the patients.
Physical examination is frequently normal, but it may also reveal temporal 
artery abnormalities such as thickness, tenderness, and hyperemia, with normal, 
decreased, or absent pulse. Even though temporal artery abnormality is one of the 
five ACR classification criteria for GCA, it is seen in less than 30% of the patients. 
Peripheral pulses in arms and legs may be decreased or absent as well in large-vessel 
disease, and arterial bruits can be heard in such patients.
4. Diagnosis
The American College of Rheumatology classification criteria for GCA, 
published in 1990, requires three or more of the following five criteria [1]: age 
50 years and older [2], new onset of localized headache [3], temporal artery 
tenderness on palpation or decreased pulsation [4], an abnormal temporal artery 
biopsy, and [5] an erythrocyte sedimentation rate (ESR) of 50 mm/h or more 
(Table 1) [7]. These criteria are designed to be classificatory and not diagnostic, 
with sensitivity and specificity of 81.1% and 64.2%, respectively [8]. In the last 
years, new imaging techniques have emerged and can be helpful tools on diagnosis 
and disease activity assessment.
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4.1 Acute-phase reactants
ESR higher than 50 mm/h is one of the five criteria for GCA classification 
according to the ACR. However, in recent years alternative acute-phase reactants 
have been proposed as more sensitive markers. Recently one study analyzed 26 
markers in GCA and PMR comparing with healthy controls and found that three 
serum markers (B cell-activating factor [BAFF], CXCL9, and IL-6) were increased 
in both newly diagnosed GCA and newly diagnosed PMR patients. Serum BAFF 
and IL-6, but not CXCL9, were attenuated upon glucocorticoid-induced remission 
and showed the strongest association with disease activity in both GCA and PMR 
patients [9]. BAFF is an important regulator of B cell responses and has been linked 
to the development of many autoimmune diseases. Even though these markers 
are not used routinely in clinical practice yet, they are promising new tools in the 
diagnostic approach and disease activity assessment in GCA.
Platelets are also considered a serum marker for inflammation in GCA. The pos-
tulated mechanism of thrombocytosis in promoting inflammation stems from their 
early interaction with the endothelium in inflammatory states during which they 
provide adhesion molecules and chemotactic stimulation to aid in the recruitment 
of leukocytes and enhance the release of different inflammatory mediators [10].
The most used tests for measuring inflammation in clinical practice are ESR 
and CRP. One study showed that the optimal cutoff value for CRP in GCA was 
26.9 mg/L (sensitivity 75% and specificity 51%) and for ESR was 53 mm/h (sensitiv-
ity 66% and specificity 55%) [11].
4.2 Temporal artery biopsy (TAB)
Even though temporal artery biopsy is not essential for the diagnosis, one study 
found that sensitivity and specificity of ACR criteria for diagnosis of GCA before 
performing TAB were 68.5 and 58%, respectively, while sensitivity and specificity of 
ACR criteria after performing TAB biopsy were 89.8 and 64.5%, respectively [12]. The 
sensitivity rates are lower in the large-vessel phenotype of GCA, and even in patients 
with the temporal artery affected, skip lesions may contribute to a negative TAB.
TAB showing transmural inflammation is still considered the gold standard for the 
diagnosis of GCA and remains the most specific diagnostic test. It is a minimally inva-
sive and well-tolerated surgical procedure that is generally performed in an outpatient 
surgery setting and carries a low risk of complications in experienced hands. The 
length of the artery needed for optimal histopathological analysis is 2 cm. For all these 
reasons, TAB is still recommended in all patients with a clinical suspicion of GCA. In 
addition to their diagnostic role, histological findings of positive TAB may have clini-
cal and prognostic significance and thus implications for the patients’ management.
1. Age ≥ 50 years 1
2. New-onset headache 1
3. Temporal artery tenderness/decreased pulsation 1
4. Abnormal temporal artery biopsy 1
5. ESR ≥ 50 mm/1st hour 1
Total
GCA defined if score ≥ 3.
Table 1. 
ACR classification criteria for GCA (1990).
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GCA is characterized histopathologically by mononuclear infiltrates in all layers 
of the arterial wall. Macrophages and T cells are present in granuloma formation, 
and multinucleated giant cells are localized close to the fragmented internal elastic 
lamina. Neutrophils, eosinophils, and plasma cells are rare. Proliferation of the 
intima results in occlusive vasculopathy. Neoangiogenesis is frequent and at times 
prominent, and fibrinoid necrosis is typically absent (Figures 1 and 2) [13].
The positivity of TAB declines after glucocorticoid treatment is started, and the 
biopsy should ideally be performed within 2 weeks from the onset of the therapy. 
Figure 1. 
Histopathological analysis of a patient from the Rheumatology Division of the University of Sao Paulo showing 
a transmural lymphomonocytary infiltrate and important narrowing of the vessel lumen. HE 100×. Image 
gently provided by the Pathological Anatomy Division of the University of Sao Paulo, School of Medicine.
Figure 2. 
Histopathological analysis of a patient from the Rheumatology Division of the University of Sao Paulo showing 
a transmural lymphomonocytary infiltrate and the presence of a granuloma. HE 100×. Image gently provided 
by the Pathological Anatomy Division of the University of Sao Paulo, School of Medicine.
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Importantly, the therapy should never be delayed for the performance of a biopsy, 
especially when visual symptoms are present [14].
For patients with a negative temporal artery biopsy, clinical assessment remains 
a mainstay of diagnosis.
4.3 Imaging techniques
In 2018, the European League Against Rheumatism (EULAR) published recom-
mendations about the use of imaging techniques in large-vessel vasculitis (LVV), 
which included GCA and Takayasu’s arteritis. According to these recommendations, 
in patients with suspected GCA, an early imaging test is recommended to comple-
ment the clinical criteria for diagnosing GCA, assuming high expertise and prompt 
availability of the imaging technique [15]. However, imaging should not delay initia-
tion of treatment. The choice of the individual imaging method depends on the pre-
dominant clinical symptoms and local settings. In settings where imaging modalities 
are not readily available or expertise with imaging in GCA is questionable, a biopsy 
should still be favored in first place. Besides, if positive histology is already available, 
additional imaging may not be needed for the diagnosis. In centers, however, where 
imaging (and TAB) is readily available and performed with high quality, the task 
force recommends that imaging should be preferred as the first test because of low 
invasiveness, ready availability of imaging results, and assessment of a larger extent 
of potentially inflamed arteries at the same examination, therefore contributing to 
a lower number of false-negative results. Imaging should be performed before or as 
early as possible after initiation of therapy, best within 1 week, because treatment 
with glucocorticoids rapidly reduces the sensitivity of imaging [15].
Figure 3. 
Temporal artery duplex scan of a patient from the Rheumatology Division of the University of Sao Paulo, 
School of Medicine with GCA showing thickness in the vascular wall and the noncompressible “halo” sign.
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In patients in whom there is a high clinical suspicion of GCA and a positive 
imaging test, the diagnosis of GCA may be made without an additional test (biopsy 
or further imaging). In patients with a low clinical probability and a negative imag-
ing result, the diagnosis of GCA can be considered unlikely [15].
Ultrasound of temporal ± axillary arteries is recommended as the first imaging 
modality in patients with suspected predominantly cranial GCA. A noncompress-
ible “halo” sign is the ultrasound finding most suggestive of GCA (Figure 3). High-
resolution MRI of cranial arteries to investigate mural inflammation may be used 
as an alternative for GCA diagnosis if ultrasound is not available or inconclusive. 
Ultrasound, PET, MRI, and/or CT may be used for the detection of mural inflam-
mation and/or luminal changes in extracranial arteries to support the diagnosis of 
large-vessel GCA (Figure 4). Ultrasound is of limited value for the assessment of 
aortitis [15].
In patients with a suspected flare, imaging might be helpful to confirm or 
exclude it. Imaging is not routinely recommended for patients in clinical and 
biochemical remission. In patients with large-vessel vasculitis, MRA, CTA, and/or 
ultrasound may be used for long-term monitoring of structural damage, particu-
larly to detect stenosis, occlusion, dilatation, and/or aneurysms [15].
5. Treatment
Treatment with oral glucocorticoid (GC) effectively induces remission and 
reduces the evolution to visual loss, and it should be started as early as possible 
Figure 4. 
PET-CT of a patient from the Rheumatology Division of the University of Sao Paulo, School of Medicine with 
GCA showing inflammation in the vascular wall of the aorta and subclavian, common carotid, iliac, femoral, 
popliteal, and tibial arteries.
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when there is a clinical suspicion of GCA. The GC therapy cannot be postponed 
to after confirmation of the diagnosis, because once the visual loss is installed, it is 
rarely reversible [16].
Oral prednisone in a daily single dose of 40–60 mg usually resolves the symp-
toms and normalizes acute inflammation reactants within the first 2–4 weeks of the 
treatment. When premonitory visual signs are present (amaurosis fugax) or when 
visual loss is installed, pulse therapy with daily intravenous methylprednisolone 
(500–1000 mg) for 3 days can be tried, even though its superiority compared to the 
oral prednisone regimen has not been proven in clinical trials.
Glucocorticoids are effective in inducing clinical remission, but the side effects 
of its chronical use are undesirable, especially in elderly individuals. Therefore, 
synthetic or biological immunosuppressants have been used as GC-sparing adju-
vants to reduce the cumulative GC dose and to maintain remission after the predni-
sone withdrawal [17]. There is no consensus on the timing of initiating GC-sparing 
therapy, but indications to start it early in the disease course include the presence 
of significant premorbid diseases (diabetes mellitus, osteoporosis, obesity), the 
emergence of significant glucocorticoid-related side effects, and a relapsing course 
necessitating protracted CS use. After clinical remission is achieved (symptoms 
resolved and laboratory inflammation markers normalized), the GC taper can be 
started. It has to be slow, especially with lower doses. The dose can gradually be 
reduced by 5 mg every 2 weeks to 20 mg/day and then by 2.5 mg every 2 weeks to 
10 mg/day if there are no flares of disease activity. After achieving a daily dose of 
10 mg, the prednisone taper should be slowed, such that patients remain on pro-
gressively decreasing doses over the ensuing 6–12 months. Tapering by 1 mg decre-
ments each month once the daily dose is less than 10 mg can be considered. Disease 
relapses are more frequent in this final phase of the GC tapering regimen [18].
5.1 Glucocorticoid-sparing therapy
Methotrexate (MTX) is the conventional immunosuppressive drug most com-
monly used for the management of refractory GCA. However, the efficacy of this 
drug in GCA is modest. The trials yielded a role of MTX (10–15 mg/week) to reduce 
the frequency of relapses (by 35% of a first relapse and by 51% of a second relapse) 
and decrease the cumulative prednisone dose. However, the optimum efficacy of 
MTX becomes manifest only after 24–36 weeks [19].
Leflunomide may also be an effective and well-tolerated glucocorticoid-sparing 
agent in GCA, but there are no randomized controlled trials to confirm it yet. In 
one prospective observational study with 76 newly diagnosed GCA patients, 10 mg 
daily leflunomide was compared with glucocorticoid only in a follow-up period of at 
least 48 weeks. During the follow-up 13.3% patients in the leflunomide group flared 
versus 39.1% in the GC-only group (p = 0.02). Furthermore, 56.7% patients in the 
leflunomide were able to stop GC at week 48 but none in the GC-only group [20].
Tocilizumab is a humanized monoclonal antibody that binds to the soluble 
and membrane-bound forms of the IL-6 receptor (IL-6R). IL-6 has a key role in 
the pathogenesis of GCA, and elevated levels of IL-6 are present and correlate with 
disease activity. Efficacy of tocilizumab in GCA has been proved in a multicenter, 
randomized, double-blind, placebo-controlled, phase 3 trial with 251 patients (119 
newly diagnosed and 132 with relapsing disease). The patients were randomized to 
receive subcutaneous tocilizumab (162 mg) weekly or every other week combined 
with a 26-week prednisone taper or placebo, combined with a prednisone taper over 
a period of either 26 or 52 weeks. Both groups of patients treated with tocilizumab 
achieved sustained remission more commonly than those placebo-treated at week 
52. Patients who underwent tocilizumab therapy had fewer relapses of disease than 
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those in the placebo arms [21]. Tocilizumab use was associated with a powerful 
glucocorticoid-sparing effect, and this effect was stronger in those patients who had 
experienced relapses before randomization. Tocilizumab in a subcutaneous weekly 
dose of 162 mg was approved by the US FDA and the European Commission for the 
treatment of GCA. However, there is concern about the characterization of a relapse 
in patients that are under tocilizumab therapy, because tocilizumab is very effective 
in normalizing CRP and ESR and some patients can be oligo-symptomatic during 
a flare. Periodic imaging in these patients is recommended for accessing vascular 
activity or progression of the vascular damage during the treatment.
Ustekinumab is a human monoclonal antibody that binds to the p40 subunit of 
both IL-12 and IL-23 preventing their binding to their shared cell surface recep-
tor chain, IL-12⁪. The inhibition of IL-12 signaling abrogates Th1 response with 
reduction in TNF-𝛼, IFN-𝛾, and IL-12 production. The inhibition of IL-23 signaling 
abrogates Th17 response with the reduction on IL-6, IL-17, IL-21, IL-22, and TNF-𝛼 
production. Th1 and Th17 responses both have important roles in the pathogenesis 
of GCA. A prospective open-label 52-week trial with 25 patients with relapsing 
GCA showed that ustekinumab may be effective for the treatment of GCA: at week 
52 the median daily dose of prednisolone decreased from 20 to 5 mg (p < 0.0001), 
and no patient experienced a relapse of GCA while receiving ustekinumab [22]. No 
randomized controlled trial with ustekinumab in GCA patients has been per-
formed yet.
Abatacept is a fully human fusion protein that binds to CD80/CD86 on antigen-
presenting cells preventing these molecules from binding to their ligand, CD28, 
on T cells, and is moderately effective in the treatment of GCA. In a multicenter, 
randomized, double-blind trial, 49 patients with GCA were treated with 10 mg/kg 
intravenous abatacept on days 1, 4, and 29 and week 8 and monthly after that. The 
relapse-free survival rate at 12 months, the primary endpoint, was 48% for those 
receiving abatacept and 31% for those receiving placebo (p = 0.049) [23]. Further 
studies encompassing larger number of patients are needed to confirm the utility of 
abatacept as adjunctive therapy in GCA.
Anti-TNF𝛼 agents have been tested and yielded disappointing results, showing 
no efficacy in reducing GC dose or relapse rates in GCA. There are other promising 
target therapies being tested, such as the JAK/STAT inhibitors, but the results are 
not available, and there is no data to support their use in clinical practice yet.
5.2 Preventing complications
Patients with GCA are elderly and frequently have multiple comorbid conditions 
that can be worsened by the use of GC and immunosuppressants. Therefore, the 
levels of vitamin D must be higher than 30 ng/mL for all patients, and the dietary 
intake of calcium must be stimulated (or supplementation, if the dietary intake is 
insufficient) for bone protection, as well as the use of bisphosphonates if indicated.
Low-dose aspirin (80–100 mg/day) should be prescribed for prevention of 
cardiovascular events, which represent the main cause of death in this population.
6. Prognosis
The most frequent causes of death in GCA patients are cardiovascular diseases 
followed by cancer. Combined, these conditions account for approximately two 
thirds of all deaths. A Norwegian cohort of 881 patients with GCA and 2577 popula-
tion controls found no significant difference in the overall cumulative survival or 
survival at any specific time after diagnosis. In this study the mean age of death was 
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83.6 (SD 7.5) years for GCA patients, and survival was more than 80% in 5 years and 
approximately 50% in 10 years [24]. The same study found that even though the 
overall mortality was not reduced in GCA, these patients have an increased risk of 
death due to circulatory diseases and infections but a decreased risk of death due to 
cancer over time. The increased risk of death by circulatory diseases may be related 
to aneurysms and dissections, which are recognized as large-vessel complications of 
GCA. Therefore, it is extremely important in the management of these patients to 
identify and to treat other contributing risk factors for circulatory disease.
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